3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
51
Rectal Neoplasms
28
Colonic Neoplasms
16
Stomach Neoplasms
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
9
Adenocarcinoma Of Esophagus
7
Esophageal Neoplasms
6
Neoplasms
5
Cholangiocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Liver Neoplasms
2
Intestinal Neoplasms
2
Gastrointestinal Neoplasms
2
Gastrointestinal Diseases
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Biliary Tract Neoplasms
2
Peritoneal Neoplasms
1
Pancreatic Adenocarcinoma
1
Operable T2-3N+M0 Rectal Cancer (Stage III)
1
Neurotoxicity Syndromes
1
Metastatic Colorectal Adenocarcinoma
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Locally Advanced Colorectal Carcinoma
1
Intestinal Diseases
1
Interventions
Gemcitabine
20
Fluorouracil
14
Cisplatin
10
Capecitabine
10
Leucovorin
8
durvalumab
6
Oxaliplatin
6
Erlotinib Hydrochloride
4
Sorafenib
3
Radiotherapy
3
trifluridine tipiracil drug combination
2
trametinib
2
regorafenib
2
pembrolizumab
2
olaparib
2
ceralasertib
2
Specimen Handling
2
Radiosurgery
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Irinotecan
2
Filgrastim
2
AZD 6244
2
zimberelimab
1
tremelimumab
1
titanium silicide
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
seribantumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bile Duct Neoplasms
×
Folfox protocol
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts